Yutrepia

Product NDC: 72964-012
11-digit product format: 729640012
Labeler code: 72964
Product ID: 72964-012_92c4515d-7de1-4bde-9ee9-f350696ba98d
Type: HUMAN PRESCRIPTION DRUG
Nonproprietary name: treprostinil
Dosage form: CAPSULE
Route: RESPIRATORY (INHALATION)
Labeler: Liquidia Technologies, Inc.
Application: NDA213005
Marketing category: NDA
Marketing start: 2025-05-23
Substance: TREPROSTINIL SODIUM
Active strength: 53 ug/1
Pharmacologic classes: Prostacycline Vasodilator [EPC], Prostaglandins I [CS], Vasodilation [PE]
NDC exclude flag: No
Listing certified through: 2026-12-31
Current FDA listing: Yes

Source provenance: Browse the complete Orange Book source catalog · source snapshot 42.

Orange Book products#

Current product rows page 1 of 1 · 4 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	RLD / RS	Approval date
N213005-001	YUTREPIA	TREPROSTINIL SODIUM	EQ 0.0265MG BASE/INH	POWDER / INHALATION	RLD, RS	2025-05-23
N213005-002	YUTREPIA	TREPROSTINIL SODIUM	EQ 0.053MG BASE/INH	POWDER / INHALATION	RLD, RS	2025-05-23
N213005-003	YUTREPIA	TREPROSTINIL SODIUM	EQ 0.0795MG BASE/INH	POWDER / INHALATION	RLD, RS	2025-05-23
N213005-004	YUTREPIA	TREPROSTINIL SODIUM	EQ 0.106MG BASE/INH	POWDER / INHALATION	RLD, RS	2025-05-23

Orange Book patents#

Current patent rows page 1 of 1 · 24 matching rows.

Application-product, Patent, Expiration table
Application-product	Patent	Expiration	Use code	Coverage / status	Submission date
N213005-001	10898494	2037-05-05	U-4200		2025-06-13
N213005-001	11660304	2037-05-05	U-4200		2025-06-13
N213005-001	11712442	2037-05-05	U-4200		2025-06-13
N213005-001	11744835	2037-05-05		Drug product	2025-06-13
N213005-001	11744836	2037-05-05		Drug product	2025-06-13
N213005-001	12390475	2037-05-05		Drug product	2025-08-29
N213005-002	10898494	2037-05-05	U-4200		2025-06-13
N213005-002	11660304	2037-05-05	U-4200		2025-06-13
N213005-002	11712442	2037-05-05	U-4200		2025-06-13
N213005-002	11744835	2037-05-05		Drug product	2025-06-13
N213005-002	11744836	2037-05-05		Drug product	2025-06-13
N213005-002	12390475	2037-05-05		Drug product	2025-08-29
N213005-003	10898494	2037-05-05	U-4200		2025-06-13
N213005-003	11660304	2037-05-05	U-4200		2025-06-13
N213005-003	11712442	2037-05-05	U-4200		2025-06-13
N213005-003	11744835	2037-05-05		Drug product	2025-06-13
N213005-003	11744836	2037-05-05		Drug product	2025-06-13
N213005-003	12390475	2037-05-05		Drug product	2025-08-29
N213005-004	10898494	2037-05-05	U-4200		2025-06-13
N213005-004	11660304	2037-05-05	U-4200		2025-06-13
N213005-004	11712442	2037-05-05	U-4200		2025-06-13
N213005-004	11744835	2037-05-05		Drug product	2025-06-13
N213005-004	11744836	2037-05-05		Drug product	2025-06-13
N213005-004	12390475	2037-05-05		Drug product	2025-08-29

Orange Book exclusivity#

Current exclusivity rows page 1 of 1 · 4 matching rows.

Application-product, Exclusivity code, Expiration table
Application-product	Exclusivity code	Expiration
N213005-001	NP	2028-05-23
N213005-002	NP	2028-05-23
N213005-003	NP	2028-05-23
N213005-004	NP	2028-05-23

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	RLD / RS	Approval date	Source SHA-256
2026-08-18 06:07:40	2026-07	N213005-001	YUTREPIA	EQ 0.0265MG BASE/INH	POWDER / INHALATION	RLD, RS	2025-05-23	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213005-002	YUTREPIA	EQ 0.053MG BASE/INH	POWDER / INHALATION	RLD, RS	2025-05-23	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213005-003	YUTREPIA	EQ 0.0795MG BASE/INH	POWDER / INHALATION	RLD, RS	2025-05-23	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213005-004	YUTREPIA	EQ 0.106MG BASE/INH	POWDER / INHALATION	RLD, RS	2025-05-23	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	N213005-001	YUTREPIA	EQ 0.0265MG BASE/INH	POWDER / INHALATION	RLD, RS	2025-05-23	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N213005-002	YUTREPIA	EQ 0.053MG BASE/INH	POWDER / INHALATION	RLD, RS	2025-05-23	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N213005-003	YUTREPIA	EQ 0.0795MG BASE/INH	POWDER / INHALATION	RLD, RS	2025-05-23	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N213005-004	YUTREPIA	EQ 0.106MG BASE/INH	POWDER / INHALATION	RLD, RS	2025-05-23	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N213005-001	YUTREPIA	EQ 0.0265MG BASE/INH	POWDER / INHALATION	RLD, RS	2025-05-23	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N213005-002	YUTREPIA	EQ 0.053MG BASE/INH	POWDER / INHALATION	RLD, RS	2025-05-23	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N213005-003	YUTREPIA	EQ 0.0795MG BASE/INH	POWDER / INHALATION	RLD, RS	2025-05-23	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N213005-004	YUTREPIA	EQ 0.106MG BASE/INH	POWDER / INHALATION	RLD, RS	2025-05-23	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	N213005-001	YUTREPIA	EQ 0.0265MG BASE/INH	POWDER / INHALATION	RLD, RS	2025-05-23	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N213005-002	YUTREPIA	EQ 0.053MG BASE/INH	POWDER / INHALATION	RLD, RS	2025-05-23	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N213005-003	YUTREPIA	EQ 0.0795MG BASE/INH	POWDER / INHALATION	RLD, RS	2025-05-23	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N213005-004	YUTREPIA	EQ 0.106MG BASE/INH	POWDER / INHALATION	RLD, RS	2025-05-23	`6a471c1ec25d…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	N213005-001	YUTREPIA	EQ 0.0265MG BASE/INH	POWDER / INHALATION	RLD, RS	2025-05-23	`a50c72e98297…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	N213005-002	YUTREPIA	EQ 0.053MG BASE/INH	POWDER / INHALATION	RLD, RS	2025-05-23	`a50c72e98297…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	N213005-003	YUTREPIA	EQ 0.0795MG BASE/INH	POWDER / INHALATION	RLD, RS	2025-05-23	`a50c72e98297…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	N213005-004	YUTREPIA	EQ 0.106MG BASE/INH	POWDER / INHALATION	RLD, RS	2025-05-23	`a50c72e98297…`

Observed Orange Book patent history#

Patent history page 1 of 3 · 116 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Patent	Expiration	Use code	Coverage / status	Submission date	Source SHA-256
2026-08-18 06:07:40	2026-07	N213005-001	10898494	2037-05-05	U-4200		2025-06-13	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213005-001	11660304	2037-05-05	U-4200		2025-06-13	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213005-001	11712442	2037-05-05	U-4200		2025-06-13	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213005-001	11744835	2037-05-05		Drug product	2025-06-13	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213005-001	11744836	2037-05-05		Drug product	2025-06-13	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213005-001	12390475	2037-05-05		Drug product	2025-08-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213005-002	10898494	2037-05-05	U-4200		2025-06-13	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213005-002	11660304	2037-05-05	U-4200		2025-06-13	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213005-002	11712442	2037-05-05	U-4200		2025-06-13	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213005-002	11744835	2037-05-05		Drug product	2025-06-13	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213005-002	11744836	2037-05-05		Drug product	2025-06-13	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213005-002	12390475	2037-05-05		Drug product	2025-08-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213005-003	10898494	2037-05-05	U-4200		2025-06-13	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213005-003	11660304	2037-05-05	U-4200		2025-06-13	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213005-003	11712442	2037-05-05	U-4200		2025-06-13	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213005-003	11744835	2037-05-05		Drug product	2025-06-13	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213005-003	11744836	2037-05-05		Drug product	2025-06-13	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213005-003	12390475	2037-05-05		Drug product	2025-08-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213005-004	10898494	2037-05-05	U-4200		2025-06-13	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213005-004	11660304	2037-05-05	U-4200		2025-06-13	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213005-004	11712442	2037-05-05	U-4200		2025-06-13	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213005-004	11744835	2037-05-05		Drug product	2025-06-13	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213005-004	11744836	2037-05-05		Drug product	2025-06-13	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213005-004	12390475	2037-05-05		Drug product	2025-08-29	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	N213005-001	10898494	2037-05-05	U-4200		2025-06-13	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N213005-001	11660304	2037-05-05	U-4200		2025-06-13	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N213005-001	11712442	2037-05-05	U-4200		2025-06-13	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N213005-001	11744835	2037-05-05		Drug product	2025-06-13	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N213005-001	11744836	2037-05-05		Drug product	2025-06-13	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N213005-001	12390475	2037-05-05		Drug product	2025-08-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N213005-002	10898494	2037-05-05	U-4200		2025-06-13	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N213005-002	11660304	2037-05-05	U-4200		2025-06-13	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N213005-002	11712442	2037-05-05	U-4200		2025-06-13	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N213005-002	11744835	2037-05-05		Drug product	2025-06-13	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N213005-002	11744836	2037-05-05		Drug product	2025-06-13	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N213005-002	12390475	2037-05-05		Drug product	2025-08-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N213005-003	10898494	2037-05-05	U-4200		2025-06-13	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N213005-003	11660304	2037-05-05	U-4200		2025-06-13	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N213005-003	11712442	2037-05-05	U-4200		2025-06-13	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N213005-003	11744835	2037-05-05		Drug product	2025-06-13	`011fe1cb6892…`

Observed Orange Book exclusivity history#

Captured, Edition, Application-product table
Captured	Edition	Application-product	Exclusivity code	Expiration	Source SHA-256
2026-08-18 06:07:40	2026-07	N213005-001	NP	2028-05-23	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213005-002	NP	2028-05-23	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213005-003	NP	2028-05-23	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213005-004	NP	2028-05-23	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	N213005-001	NP	2028-05-23	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N213005-002	NP	2028-05-23	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N213005-003	NP	2028-05-23	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N213005-004	NP	2028-05-23	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N213005-001	NP	2028-05-23	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N213005-002	NP	2028-05-23	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N213005-003	NP	2028-05-23	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N213005-004	NP	2028-05-23	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	N213005-001	NP	2028-05-23	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N213005-002	NP	2028-05-23	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N213005-003	NP	2028-05-23	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N213005-004	NP	2028-05-23	`6a471c1ec25d…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	N213005-001	NP	2028-05-23	`a50c72e98297…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	N213005-002	NP	2028-05-23	`a50c72e98297…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	N213005-003	NP	2028-05-23	`a50c72e98297…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	N213005-004	NP	2028-05-23	`a50c72e98297…`

Additional Listing Data#

Finished product: Yes
Brand name base: Yutrepia
Listing expiration: 2026-12-31

Active Ingredients#

Ingredient, Strength table
Ingredient	Strength
TREPROSTINIL SODIUM	53 ug/1

Harmonized UNII identifiers#

UNII identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
Identifier	FDA.report destination
7JZ75N2NT6	Internal UNII lookup

Harmonized RxCUI identifiers#

RxCUI identifiers page 1 of 1 · 8 matching rows.

Identifier, FDA.report destination table
Identifier	FDA.report destination
2714659	Internal RxNorm lookup
2714664	Internal RxNorm lookup
2714666	Internal RxNorm lookup
2714668	Internal RxNorm lookup
2714670	Internal RxNorm lookup
2714672	Internal RxNorm lookup
2714674	Internal RxNorm lookup
2714676	Internal RxNorm lookup

Harmonized SPL set identifiers#

SPL set identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
Identifier	FDA.report destination
e8f6d534-115c-440e-bdbb-b443a29bb468	Available on FDA.report

DailyMed Product Concepts#

Product concept, Relation, Version table
Product concept	Relation	Version	Effective
d31d7280-9cbd-4e8c-ad8c-a830d9d6c4bf	Product name	1	20260309
3a764347-294a-401b-979f-44c1c6bb101a	Product name	1	20230126
5e14eefc-ad08-9fbf-a28c-67c518b16369	Product name	5	20210727
799cd7a2-692a-4730-993b-8b702e954a56	Product name	1	20200407
0ca1d589-929b-4b33-bc5b-1d84abdafa6a	Product name	1	20150324
fc363c46-397b-4476-ac0f-70e43e8e4592	Product name	1	20150324

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDC	Product	Description	Form	Quantity	Strength	SPL version
72964-012-01	Yutrepia	7 in 1 CARTON	CAPSULE	7		3
72964-012-01	Yutrepia	4 in 1 BLISTER PACK	CAPSULE	4		3

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDC	Billing unit	Product NDC	DailyMed indexing SPL	SPL version	Effective
72964-012-01	EA - Each	72964-012	6f741704-35e3-4fcc-a5e8-87aff55e8f2a	1	2025-06-13

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDC	Dashboard title	SPL version	Validation	Dashboard ZIP
72964-012	YUTREPIA (TREPROSTINIL) CAPSULE [LIQUIDIA TECHNOLOGIES, INC.]	1	Current NDC, 2 package rows	20250529_e8f6d534-115c-440e-bdbb-b443a29bb468.zip

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Yutrepia	TREPROSTINIL	Liquidia Technologies, Inc.	e8f6d534-115c-440e-bdbb-b443a29bb468	2025-09-08	Warnings, Adverse reactions	Exact identifier application applno (NDA): 213005 application number: NDA213005 ndc (product): 72964-012

UNII, Preferred term, Registry number table
UNII	Preferred term	Registry number	Matched term
7JZ75N2NT6	TREPROSTINIL SODIUM	289480-64-4	TREPROSTINIL SODIUM
RUM6K67ESG	TREPROSTINIL	81846-19-7	treprostinil

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUI	RxNorm string	TTY	DailyMed	SPL version
2714674	treprostinil 106 MCG Inhalation Powder	PSN	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714659	treprostinil 26.5 MCG Inhalation Powder	PSN	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714666	treprostinil 53 MCG Inhalation Powder	PSN	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714670	treprostinil 79.5 MCG Inhalation Powder	PSN	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714676	Yutrepia 106 MCG Inhalation Powder	PSN	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714664	Yutrepia 26.5 MCG Inhalation Powder	PSN	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714668	Yutrepia 53 MCG Inhalation Powder	PSN	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714672	Yutrepia 79.5 MCG Inhalation Powder	PSN	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714664	treprostinil 0.0265 MG Inhalation Powder [Yutrepia]	SBD	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714668	treprostinil 0.053 MG Inhalation Powder [Yutrepia]	SBD	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714672	treprostinil 0.0795 MG Inhalation Powder [Yutrepia]	SBD	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714676	treprostinil 0.106 MG Inhalation Powder [Yutrepia]	SBD	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714659	treprostinil 0.0265 MG Inhalation Powder	SCD	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714666	treprostinil 0.053 MG Inhalation Powder	SCD	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714670	treprostinil 0.0795 MG Inhalation Powder	SCD	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714674	treprostinil 0.106 MG Inhalation Powder	SCD	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714674	treprostinil 106 MCG (as treprostinil sodium) Inhalation Powder	SY	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714674	treprostinil 106 MCG Inhalation Powder	SY	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714659	treprostinil 26.5 MCG (equivalent to treprostinil sodium 28 MCG) Inhalation Powder	SY	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714659	treprostinil 26.5 MCG Inhalation Powder	SY	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714666	treprostinil 53 MCG (as treprostinil sodium) Inhalation Powder	SY	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714666	treprostinil 53 MCG Inhalation Powder	SY	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714670	treprostinil 79.5 MCG (as treprostinil sodium) Inhalation Powder	SY	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714670	treprostinil 79.5 MCG Inhalation Powder	SY	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714664	Yutrepia 0.0265 MG Inhalation Powder	SY	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714668	Yutrepia 0.053 MG Inhalation Powder	SY	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714672	Yutrepia 0.0795 MG Inhalation Powder	SY	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714676	Yutrepia 0.106 MG Inhalation Powder	SY	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714676	Yutrepia 106 MCG (as treprostinil sodium) Inhalation Powder	SY	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714676	Yutrepia 106 MCG Inhalation Powder	SY	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714664	Yutrepia 26.5 MCG (equivalent to treprostinil sodium 28 MCG) Inhalation Powder	SY	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714664	Yutrepia 26.5 MCG Inhalation Powder	SY	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714668	Yutrepia 53 MCG (as treprostinil sodium) Inhalation Powder	SY	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714668	Yutrepia 53 MCG Inhalation Powder	SY	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714672	Yutrepia 79.5 MCG (as treprostinil sodium) Inhalation Powder	SY	e8f6d534-115c-440e-bdbb-b443a29bb468	3
2714672	Yutrepia 79.5 MCG Inhalation Powder	SY	e8f6d534-115c-440e-bdbb-b443a29bb468	3

Packages#

Package NDC, 11-digit format, Description table
Package NDC	11-digit format	Description	Units	Marketing start	Sample	Exclude flag	Status
72964-012-01	72964001201	7 BLISTER PACK in 1 CARTON (72964-012-01) / 4 CAPSULE in 1 BLISTER PACK / 1 CAPSULE in 1 CAPSULE	7 blister pack	2025-05-23	No	No	Current

Title, Manufacturer, Effective date table
Title	Manufacturer	Effective date	Type	Version
Yutrepia - Liquidia Technologies, Inc.	Liquidia Technologies, Inc.	2025-09-08	HUMAN PRESCRIPTION DRUG LABEL	3